N-(4,6-dimethoxy-2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)-3,3-dimethylbutanamide | 1354712-92-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4,6-dimethoxy-2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)-3,3-dimethylbutanamide
• 英文别名: N-[4,6-dimethoxy-2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]-3,3-dimethylbutanamide
• CAS: 1354712-92-7
• 化学式: C₁₈H₃₀N₄O₄
• 分子量: 366.461
• InChiKey: XHJMCIALHJMEBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氯-4,6-二甲氧基-5-硝基嘧啶 在 palladium on carbon 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 5.0h， 生成 N-(4,6-dimethoxy-2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)-3,3-dimethylbutanamide
  参考文献：
  名称：

  [EN] PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS
  [FR] AMIDES PIPÉRIDINYL PYRIMIDINE EN TANT QU'OUVREURS DU CANAL POTASSIQUE KO7

  摘要：

  本发明涉及公式（I）所述的化合物或其药学上可接受的盐，包括该化合物或其药学上可接受的盐的制药组合物以及治疗或制造用于治疗中枢神经系统疾病，障碍或病况的药物，包括双相情感障碍，抑郁障碍，焦虑障碍，认知障碍，疼痛障碍，泌尿生殖障碍和癫痫等其他疾病，障碍或病况，可以作为单一治疗或与另一种活性药物成分联合使用。

  公开号：

  WO2012004698A1

文献信息

• Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers
  申请人：Claffey Michelle Marie

  公开号：US20130150391A1

  公开（公告）日：2013-06-13

  The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及一种式（I）的化合物或其药学上可接受的盐，包括含有式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗中枢神经系统疾病、失调或症状的方法，包括双相情感障碍、抑郁症、焦虑症、认知障碍、疼痛障碍、泌尿生殖障碍和癫痫等疾病、失调或症状，可以作为单一疗法或与其他活性药物成分联合使用的制药品的制造方法。
• Piperidinyl pyrimidine amides as Kv7 potassium channel openers
  申请人：Claffey Michelle Marie

  公开号：US08883812B2

  公开（公告）日：2014-11-11

  The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

  本发明涉及式（I）的化合物或其药学上可接受的盐，以及包含式（I）的化合物或其药学上可接受的盐的制药组合物，以及用于治疗或制造用于治疗中枢神经系统疾病、障碍或病况的药物，包括双相情感障碍、抑郁障碍、焦虑障碍、认知障碍、疼痛障碍、泌尿生殖障碍和癫痫等其他在本文中讨论的疾病、障碍或病况，可以作为单一疗法或与另一种活性药物成分联合使用。
• Discovery of a novel Kv7 channel opener as a treatment for epilepsy
  作者：Jennifer E. Davoren、Michelle M. Claffey、Sheri L. Snow、Matthew R. Reese、Gaurav Arora、Christopher R. Butler、Brian P. Boscoe、Lois Chenard、Shari L. DeNinno、Susan E. Drozda、Allen J. Duplantier、Ludivine Moine、Bruce N. Rogers、SuoBao Rong、Katherine Schuyten、Ann S. Wright、Lei Zhang、Kevin A. Serpa、Mark L. Weber、Polina Stolyar、Tammy L. Whisman、Karen Baker、Karen Tse、Alan J. Clark、Haojing Rong、Robert J. Mather、John A. Lowe

  DOI：10.1016/j.bmcl.2015.04.074

  日期：2015.11

  Facilitating activation, or delaying inactivation, of the native Kv7 channel reduces neuronal excitability, which may be beneficial in controlling spontaneous electrical activity during epileptic seizures. In an effort to identify a compound with such properties, the structure-activity relationship (SAR) and in vitro ADME for a series of heterocyclic Kv7.2-7.5 channel openers was explored. PF-05020182 (2) demonstrated suitable properties for further testing in vivo where it dose-dependently decreased the number of animals exhibiting full tonic extension convulsions in response to corneal stimulation in the maximal electroshock (MES) assay. In addition, PF-05020182 (2) significantly inhibited convulsions in the MES assay at doses tested, consistent with in vitro activity measure. The physiochemical properties, in vitro and in vivo activities of PF-05020182 (2) support further development as an adjunctive treatment of refractory epilepsy. (C) 2015 Elsevier Ltd. All rights reserved.
• PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS
  申请人：Pfizer Inc.

  公开号：EP2590961A1

  公开（公告）日：2013-05-15
• US8883812B2
  申请人：——

  公开号：US8883812B2

  公开（公告）日：2014-11-11